PAP
CADL icon

Persistent Asset Partners’s Candel Therapeutics CADL Stock Holding History

Persistent Asset Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,918
Closed -$33.4K – 187
2025
Q1 		$33.4K Sell
5,918
-128
-2% -$1.05K 0.03% 142
2024
Q4 		$42.7K Buy
+6,046
New +$35.7K 0.04% 117

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Persistent Asset Partners's CADL Position: Q2 2025 in Review

Persistent Asset Partners sold out of Candel Therapeutics (CADL) in Q2 2025, closing a stake of 5,918 shares — an estimated $33.4K sold.

Persistent Asset Partners first reported a position in CADL in Q4 2024 and held it in 2 quarters. The position peaked at $42.7K in Q4 2024. 78 funds tracked by Wall St. Rank hold CADL as of Q2 2025.

  • Persistent Asset Partners reported no remaining Candel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 5,918 Candel Therapeutics shares in Q2 2025, an estimated $33.4K.
  • Persistent Asset Partners first reported a position in Candel Therapeutics in Q4 2024 and held it in 2 quarters.
  • Persistent Asset Partners's Candel Therapeutics position peaked at $42.7K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2025.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.